SPL

1.11%

9.1¢ starpharma holdings limited

Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-42

First 42 Last

Share
Profile

Follow
peony-rose

2,834 Posts.

138

08/04/24

15:22

Post #: 73241923
Share

Originally posted by sarge17: ↑

My more considered take below, and all IMHO.

I can’t help but think Starpharma are getting owned and outmanoeuvred here. But beggars can’t be choosers.

Medixci could have invested directly in Starpharma via equity placement if they liked the tech and company so much. But they didn’t.

Medicxi could have given Starpharma non-dilutive funding in exchange for a future revenue stream from current and future commercialised products if they believed in Starpharma’s potential. But they didn’t.

Medicxi via this startup company start-up company Petalion Therapeutics could have licenced one of Starpharma’s existing pre-clinical drug candidates to develop further which would have expedited getting a drug to market. But they didn’t.

Medicxi via this start-up company could have licenced DEP-Irinotecan, DEP-Cabazitaxel or DEP-Docetaxel to take into Phase 3 trials. But they didn’t.

Instead of cash going into the bank account through a licence fee, Starpharma are instead giving away their valuable IP for equity in a start-up company that they will have a minority share in, with no control, with the real potential to get diluted down the track through circumstances, developments and decisions outside of Starpharma’s control.

IMO this research agreement and collaboration is weak and not in Starpharma’s interests. It smells. It may also be an insight into the weakness of Starpharma’s prospects going forward.

Expand

Sarge, instead of you focusing on what they didn't do, take a step back and think about what they DID DO!

Medixci see potential in what SPL have and have gained access to the technology for other cancer therapies. They have other products in mind to develop and want what SPL have got. That is what they did do.

Obviously the belief in the DEP technology and commercialisation into products is still out there. It has been shown with this announcement with Medixci. That is what they did do.

SPL Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

STX

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

BRX

Belararox delineates another porphyry in Argentina at Tambo South

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

GYG

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

FHE

Frontier Energy achieves key milestone for Waroona energy project

There are more pages in this discussion • 107 more messages in this thread...

First 42 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.1¢		Change 0.001(1.11%)		Mkt cap ! $37.49M

Open	High	Low	Value	Volume
9.1¢	9.3¢	8.9¢	$196.0K	2.178M

Buyers (Bids)

No.	Vol.	Price($)
1	164414	9.1¢

Sellers (Offers)

Price($)	Vol.	No.
9.5¢	15150	1

View Market Depth

No.	Vol.	Price($)
1	164414	0.091
2	29795	0.090
3	123168	0.089
2	150000	0.088
1	10000	0.087

Price($)	Vol.	No.
0.095	15150	1
0.096	30000	2
0.100	73848	3
0.105	375912	5
0.110	45099	6

Last trade - 16.10pm 21/06/2024 (20 minute delay)

SPL (ASX) Chart

Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-42

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Cultural heritage agreement puts Walford Creek exploration back on the map

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Frontier Energy achieves key milestone for Waroona energy project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-42

Top Stories

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Belararox delineates another porphyry in Argentina at Tambo South

Cultural heritage agreement puts Walford Creek exploration back on the map

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Frontier Energy achieves key milestone for Waroona energy project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News